Morphic (MORF) - 2024 Q2 - Quarterly Report

• successful enrollment of patients in, and the completion of, our clinical trials with favorable results; • receiving required regulatory authorizations for the development and approvals for the commercialization of our product candidates; • establishing and maintaining arrangements with third-party manufacturers; • obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and their components; • enforcing and defending our intellectual property righ ...